JP2023504568A - 環状ｒｎａ組成物及び方法 - Google Patents

環状ｒｎａ組成物及び方法 Download PDF

Info

Publication number
JP2023504568A
JP2023504568A JP2022534346A JP2022534346A JP2023504568A JP 2023504568 A JP2023504568 A JP 2023504568A JP 2022534346 A JP2022534346 A JP 2022534346A JP 2022534346 A JP2022534346 A JP 2022534346A JP 2023504568 A JP2023504568 A JP 2023504568A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
rna polynucleotide
group
human
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534346A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021113777A5 (https=
JP2023504568A5 (https=
Inventor
ブライアン グッドマン
ロバート アレキサンダー ヴェッセルホーフト
アレン ティー． ホーホタ
ジュンフン ヤン
クリステン オット
Original Assignee
オルナ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オルナ セラピューティクス インコーポレイテッド filed Critical オルナ セラピューティクス インコーポレイテッド
Publication of JP2023504568A publication Critical patent/JP2023504568A/ja
Publication of JPWO2021113777A5 publication Critical patent/JPWO2021113777A5/ja
Publication of JP2023504568A5 publication Critical patent/JP2023504568A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022534346A 2019-12-04 2020-12-04 環状ｒｎａ組成物及び方法 Pending JP2023504568A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962943779P 2019-12-04 2019-12-04
US201962943797P 2019-12-04 2019-12-04
US62/943,779 2019-12-04
US62/943,797 2019-12-04
US202062972194P 2020-02-10 2020-02-10
US62/972,194 2020-02-10
US202063022248P 2020-05-08 2020-05-08
US63/022,248 2020-05-08
US202063087582P 2020-10-05 2020-10-05
US63/087,582 2020-10-05
PCT/US2020/063494 WO2021113777A2 (en) 2019-12-04 2020-12-04 Circular rna compositions and methods

Publications (3)

Publication Number Publication Date
JP2023504568A true JP2023504568A (ja) 2023-02-03
JPWO2021113777A5 JPWO2021113777A5 (https=) 2023-12-13
JP2023504568A5 JP2023504568A5 (https=) 2023-12-13

Family

ID=76222668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534346A Pending JP2023504568A (ja) 2019-12-04 2020-12-04 環状ｒｎａ組成物及び方法

Country Status (9)

Country Link
US (4) US11679120B2 (https=)
EP (2) EP4289951A3 (https=)
JP (1) JP2023504568A (https=)
CN (2) CN115052635B (https=)
AU (1) AU2020397956A1 (https=)
CA (1) CA3160739A1 (https=)
ES (1) ES2961245T3 (https=)
MX (1) MX2022006854A (https=)
WO (1) WO2021113777A2 (https=)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021236952A1 (en) * 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
MX2023002439A (es) 2020-09-03 2023-05-09 Flagship Pioneering Innovations Vi Llc Composiciones immunogénicas y usos de las mismas.
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
CN115997018A (zh) 2021-03-10 2023-04-21 尔知渃米斯股份有限公司 自身环化rna构建体
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
EP4359521A4 (en) * 2021-06-25 2025-12-17 Univ Leland Stanford Junior COMPOSITIONS AND METHOD FOR IMPROVED PROTEIN TRANSLATION FROM RECOMBINANT CIRCULAR RNAS
IL309767A (en) * 2021-07-13 2024-02-01 Generation Bio Co Single chain variable fragment (scfv) modified lipid nanoparticle compositions and uses thereof
CN114591952B (zh) * 2021-08-13 2024-06-25 苏州科锐迈德生物医药科技有限公司 一种组织特异性表达的环状rna分子及其应用
WO2023039594A1 (en) 2021-09-13 2023-03-16 Ganna Bio, Inc. Glycan conjugate compositions and methods
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
ES2994006T3 (en) 2021-09-17 2025-01-16 Flagship Pioneering Innovations Vi Llc Compositions and methods for producing circular polyribonucleotides
CA3233336A1 (en) * 2021-09-26 2023-03-30 Center For Excellence In Molecular Cell Science, Chinese Academy Of Sciences Circular rna and preparation method thereof
JP2024538144A (ja) 2021-10-18 2024-10-18 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ポリリボヌクレオチドを精製するための組成物及び方法
MX2024006440A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones inmunogenicas y sus usos.
EP4436984A1 (en) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Coronavirus immunogen compositions and their uses
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
JP2024546855A (ja) 2021-12-17 2024-12-26 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 変性条件下での環状ｒｎａの濃縮方法
KR20240117149A (ko) 2021-12-22 2024-07-31 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
MX2024007870A (es) 2021-12-23 2024-08-15 Flagship Pioneering Innovations Vi Llc Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
EP4486728A4 (en) * 2022-03-02 2026-02-25 Barcode Nanotech Ltd IONIZABLE LIPIDS AND COMPOSITIONS CONTAINING THEM
CN114507691A (zh) * 2022-03-02 2022-05-17 深圳市瑞吉生物科技有限公司 一种用于制备环状rna的载体及其应用
EP4499607A1 (en) 2022-03-25 2025-02-05 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
CN119013404A (zh) * 2022-04-06 2024-11-22 新加坡科技研究局 用于产生环状rna的载体
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー ワクチン及び関連する方法
US12297285B2 (en) * 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN115786374B (zh) * 2022-07-06 2023-10-13 广州吉赛生物科技股份有限公司 一种利用鱼腥藻内含子自剪切核酶精准制备环状rna的方法
JP2025525778A (ja) 2022-08-01 2025-08-07 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 免疫調節タンパク質及び関連方法
AU2023334610A1 (en) 2022-08-31 2025-03-13 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
US12247202B2 (en) * 2022-09-10 2025-03-11 Exclcirc (Suzhou) Biomedical Co., Ltd. Circular RNAS and preparation methods thereof
EP4584252A1 (en) * 2022-09-11 2025-07-16 Barcode Nanotech Ltd. Ionizable lipids and compositions comprising same
EP4596605A4 (en) * 2022-09-30 2026-01-14 Xiamen Sinopeg Biotech Co Ltd PEGYLATED LIPID CONTAINING A LYSIN NUCLEUS
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
EP4605009A2 (en) 2022-10-21 2025-08-27 GanNA Bio, Inc. Glycan conjugate compositions and methods
AU2023372397A1 (en) 2022-10-31 2025-05-08 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
CN115927592B (zh) * 2022-11-07 2024-06-28 中南大学湘雅医院 Csde1基因为靶点在制备用于治疗非酒精性脂肪肝的药物中的应用
CN120390656A (zh) 2022-11-08 2025-07-29 欧纳医疗公司 环状rna组合物
EP4615465A1 (en) 2022-11-08 2025-09-17 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
AU2023398825A1 (en) 2022-12-15 2025-06-26 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
IL322468A (en) 2023-02-13 2025-09-01 Flagship Pioneering Innovations Vii Llc Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
CN116411023B (zh) * 2023-02-24 2025-08-12 北京大学人民医院 一种新型环状rna成环序列构建car-t细胞及在治疗小细胞肺癌中的应用
WO2024192420A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions comprising polyribonucleotides and uses thereof
EP4680276A1 (en) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
WO2024216128A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2024216191A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
EP4698150A1 (en) 2023-04-19 2026-02-25 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
EP4464713A1 (en) 2023-05-18 2024-11-20 Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii Circular rna analogs, preparation and application thereof
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
CN119265241A (zh) 2023-06-30 2025-01-07 深圳菁童生命科学有限公司 一种无相分离转录因子介导启始阶段重编程使细胞年轻化的方法
WO2025011502A1 (zh) * 2023-07-07 2025-01-16 仁景(苏州)生物科技有限公司 制备环状rna方法及用于所述方法的核酸序列
AU2024299627A1 (en) 2023-07-25 2026-01-22 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
AU2024344058A1 (en) 2023-09-18 2026-04-02 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
WO2025106670A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025120230A1 (en) 2023-12-07 2025-06-12 T-Curx Gmbh Method of producing leukocytes expressing artificial antigen receptors
WO2025124548A1 (zh) * 2023-12-13 2025-06-19 上海瑞宏迪医药有限公司 一种咪唑类脂质及其应用
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025250751A1 (en) 2024-05-31 2025-12-04 Orna Therapeutics, Inc. Circular rna compositions and methods
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026006593A1 (en) 2024-06-28 2026-01-02 Orna Therapeutics, Inc. Synthetic internal ribosome entry sites
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2026055543A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Modified dna compositions and related methods
WO2026055547A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
WO2026064313A1 (en) 2024-09-17 2026-03-26 Flagship Pioneering Innovations Vii, Llc Rna compositions and related methods
WO2026072709A1 (en) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Chimeric antigen receptors targeting bcma
CN121737128A (zh) * 2026-03-02 2026-03-27 合肥综合性国家科学中心大健康研究院 一种提高环状rna稳定性的序列优化方法及应用和产品

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532721A (ja) * 2015-09-17 2018-11-08 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 治療剤の細胞内送達のための化合物および組成物
JP2018533573A (ja) * 2015-10-28 2018-11-15 アキィタス・セラピューティクス・インコーポレイテッドＡｃｕｉｔａｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2948884A1 (de) 1979-12-05 1981-06-11 Basf Ag, 6700 Ludwigshafen 2-hydroxypropylimidazole, verfahren zu ihrer herstellung und verwendung als oelloesliche korrosionsinhibitoren
US4661450A (en) 1983-05-03 1987-04-28 Molecular Genetics Research And Development Limited Partnership Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
JPH07502898A (ja) 1992-01-13 1995-03-30 デューク・ユニバーシティー 酵素ｒｎａ分子
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
DK148292D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
US5591737A (en) 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US6096880A (en) 1993-04-15 2000-08-01 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5434261A (en) 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
HUT75224A (en) 1993-10-19 1997-04-28 Merck & Co Inc Combination of bisphosphonates and growth hormone secretagogues
AU686780B2 (en) 1994-03-11 1998-02-12 Merck & Co., Inc. Composition for the treatment of lung disease
CA2144940A1 (en) 1994-03-18 1995-09-19 Chikara Murakata Therapeutic agent for thrombocytopenia and indolocarbazole derivatives
US5656606A (en) 1995-02-17 1997-08-12 Merck & Co., Inc. Camphor compounds promote release of growth hormone
US5747485A (en) 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
GB2308064A (en) 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
US5700549A (en) 1996-06-24 1997-12-23 International Business Machines Corporation Structure to reduce stress in multilayer ceramic substrates
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
EP0897908A1 (de) 1997-08-19 1999-02-24 Roche Diagnostics GmbH 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US6211174B1 (en) 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
US5948902A (en) 1997-11-20 1999-09-07 South Alabama Medical Science Foundation Antisense oligonucleotides to human serine/threonine protein phosphatase genes
WO1999035281A1 (en) 1998-01-09 1999-07-15 University Of Utah Research Foundation Method for in vitro amplification of circular dna
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
CA2400634A1 (en) 2000-02-17 2001-08-23 Chester Li Genetic modification of the lung as a portal for gene delivery
BRPI0109522B8 (pt) 2000-03-28 2017-04-11 Farm Bioindustries Pty Ltd construto genético linear e métodos para gerar planta transgênica ou progênie da mesma resistente a vírus ssdna e planta ou parte da mesma geneticamente modificada
EP1355159A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verwendungen von Fragmenten der Carbamoylphosphat Synthetase 1 (CPS 1) für die Diagnose von Entzündungserkrankungen und Sepsis
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
CN1882548A (zh) 2003-10-24 2006-12-20 奥斯佩克斯制药公司 2,6－二异丙基苯酚的pH敏感性前药
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
US9006487B2 (en) 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
WO2007044627A2 (en) 2005-10-06 2007-04-19 Sloan Kettering Institute For Cancer Research Compositions and methods for delivery of interfering rna
CN101016264A (zh) 2007-01-22 2007-08-15 西安新安医药科技有限公司 用于治疗的硝基咪唑衍生物、制备方法及用途
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
US8283344B2 (en) 2007-09-10 2012-10-09 Merck & Co., Inc. Method of treating inherited severe neutropenia
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
JP5147612B2 (ja) 2008-09-11 2013-02-20 本田技研工業株式会社 自動二輪車のレギュレータ冷却構造
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
WO2010084371A1 (en) 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
US20100305197A1 (en) * 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
US20120157401A1 (en) 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
JP5267874B2 (ja) 2009-07-24 2013-08-21 ソニー株式会社 信号処理装置、及び、信号処理方法
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
KR20110095439A (ko) 2010-02-19 2011-08-25 건국대학교 산학협력단 암모니움 이미다졸륨 염 및 이를 함유하는 염료감응 태양전지용 전해질 조성물
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
EP3354644A1 (en) 2011-06-08 2018-08-01 Translate Bio, Inc. Cleavable lipids
GB2496898B (en) 2011-11-25 2020-10-28 Petroliam Nasional Berhad Petronas Corrosion inhibition
JP6284181B2 (ja) 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 環状ｒｎａ及びタンパク質の製造方法
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
ES2746803T3 (es) 2013-05-15 2020-03-06 Robert Kruse Traducción intracelular de ARN circular
EP3017013A4 (en) 2013-05-28 2017-01-25 Yanjie Xu Refrigeration system with dual refrigerants and liquid working fluids
US8805972B1 (en) 2013-06-26 2014-08-12 Kaspersky Lab Zao Multi-platform operational objective configurator for computing devices
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US9593077B2 (en) 2013-11-18 2017-03-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
ES2895651T3 (es) * 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
EP4219532A3 (en) 2015-06-05 2023-08-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
JP6685039B2 (ja) 2015-08-26 2020-04-22 国立大学法人東北大学 化合物、イオン液体、白金族元素の抽出剤、白金族元素の抽出方法
LU92830B1 (en) 2015-09-15 2017-04-03 Luxembourg Inst Of Health Lih Biomarkers for heart failure
CN105176981B (zh) 2015-09-17 2017-03-15 广州永诺健康科技有限公司 用于环状rna表达的dna序列和表达载体及其应用
EP3356556B1 (en) 2015-09-29 2019-12-11 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft A method for diagnosing a disease by detection of circrna in bodily fluids
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
AU2017205101B2 (en) 2016-01-08 2023-05-04 Breast Cancer Now Inhibitors of ataxia-telangiectasia mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
EP3458106A4 (en) 2016-05-18 2020-03-18 Modernatx, Inc. POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
EP3458104A1 (en) 2016-05-18 2019-03-27 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
WO2017201348A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
KR20230074598A (ko) 2016-05-18 2023-05-30 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
MA45036A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
KR102469450B1 (ko) 2016-05-18 2022-11-22 모더나티엑스, 인크. 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
EP3472193A4 (en) 2016-06-20 2020-01-08 The Board of Trustees of the Leland Stanford Junior University CIRCULAR RNA AND THEIR USE IN IMMUNOMODULATION
US20180010175A1 (en) 2016-09-22 2018-01-11 Bio-Rad Laboratories, Inc. Methods and compositions for cloning circular rna
SG11201903674YA (en) 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
US20190290694A1 (en) 2016-12-21 2019-09-26 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
EP3564375A4 (en) 2016-12-27 2020-12-16 The University Of Tokyo ARNM FUNCTIONALIZATION PROCESS
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
CN106801050B (zh) 2017-02-20 2020-01-14 广州永诺生物科技有限公司 一种环状rna高通量测序文库的构建方法及其试剂盒
US20200368162A1 (en) 2017-02-24 2020-11-26 Modernatx, Inc. Nucleic Acid-Based Therapy of Muscular Dystrophies
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
SMT202300097T1 (it) 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
US11753434B2 (en) 2017-04-14 2023-09-12 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
EP3630966B1 (en) 2017-05-31 2025-04-23 Vilnius University Production of cyclic adenylates and their use as allosteric regulators
US11756183B2 (en) 2017-06-23 2023-09-12 Cornell University RNA molecules, methods of producing circular RNA, and treatment methods
IL316195A (en) 2017-12-15 2024-12-01 Flagship Pioneering Innovations Vi Llc Preparations containing circular polyribonucleotides and uses thereof
JP2021512090A (ja) 2018-01-30 2021-05-13 モデルナティーエックス， インコーポレイテッド 免疫細胞に薬剤を送達するための組成物及び方法
CN111954542A (zh) 2018-02-01 2020-11-17 塔夫茨大学信托人 脂质样纳米复合物及其用途
US12083224B2 (en) 2018-03-30 2024-09-10 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
JP2021523110A (ja) 2018-05-01 2021-09-02 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子発現のためのナノ粒子及びその使用
WO2019222275A2 (en) 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins
CA3100276A1 (en) * 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
WO2020010242A1 (en) 2018-07-03 2020-01-09 Washington State University Pharmaceutical agents for use in smoking and tobacco cessation
CA3107456A1 (en) 2018-07-24 2020-01-30 Mayo Foundation For Medical Education And Research Circularized engineered rna and methods
JP7283669B2 (ja) 2018-08-17 2023-05-30 チャンチョウ ピエン ツェ フアン ファーマシューティカル カンパニー リミテッド ３－アリールオキシ－３－アリール－プロピルアミン化合物およびその用途
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN113271926A (zh) * 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
CN113661242A (zh) 2019-03-25 2021-11-16 旗舰创业创新第六有限责任公司 包含经修饰的环状多核糖核苷酸的组合物及其用途
WO2020237227A1 (en) * 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
CN114007655A (zh) 2019-06-14 2022-02-01 旗舰创业创新第六有限责任公司 用于细胞疗法的环状rna
EP4022069A4 (en) 2019-08-28 2023-12-20 The Board of Trustees of the Leland Stanford Junior University MODIFIED CIRCULAR RNAS AND METHOD OF USE THEREOF
WO2021055849A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
EP3819377A1 (en) 2019-11-08 2021-05-12 Justus-Liebig-Universität Gießen Circular rna and uses thereof for inhibiting rna-binding proteins
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532721A (ja) * 2015-09-17 2018-11-08 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 治療剤の細胞内送達のための化合物および組成物
JP2018533573A (ja) * 2015-10-28 2018-11-15 アキィタス・セラピューティクス・インコーポレイテッドＡｃｕｉｔａｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLECULAR CELL, vol. 74, JPN6025046870, 2 May 2019 (2019-05-02), pages 508 - 520, ISSN: 0005731619 *
NATURE COMMUNICATIONS, vol. 9, JPN6025046869, 2018, pages 2629, ISSN: 0005731618 *

Also Published As

Publication number Publication date
US11771715B2 (en) 2023-10-03
US20220323480A1 (en) 2022-10-13
US20230062665A1 (en) 2023-03-02
US11679120B2 (en) 2023-06-20
AU2020397956A1 (en) 2022-07-07
US20230058784A1 (en) 2023-02-23
MX2022006854A (es) 2022-11-30
ES2961245T3 (es) 2024-03-11
EP4289951A2 (en) 2023-12-13
CA3160739A1 (en) 2021-06-10
EP3920976B1 (en) 2023-07-19
EP4289951A3 (en) 2024-03-13
CN115052635A (zh) 2022-09-13
CN121422256A (zh) 2026-01-30
CN115052635B (zh) 2025-07-22
US20240131049A1 (en) 2024-04-25
WO2021113777A3 (en) 2021-09-02
WO2021113777A2 (en) 2021-06-10
EP3920976A2 (en) 2021-12-15
US11766449B2 (en) 2023-09-26

Similar Documents

Publication Publication Date Title
US11766449B2 (en) Circular RNA compositions and methods
JP2023525270A (ja) 環状ｒｎａ組成物及び方法
US12180138B2 (en) Lipid nanoparticle compositions for delivering circular polynucleotides
US20250283073A1 (en) Circular RNA Compositions and Methods
US20240245805A1 (en) Circular rna compositions and methods
EP4408825A1 (en) Lipid nanoparticle compositions for delivering circular polynucleotides
US12297285B2 (en) Circular RNA encoding chimeric antigen receptors targeting BCMA
JP7851254B2 (ja) 環状ｒｎａ組成物及び方法
HK40104442A (en) Circular rna compositions and methods
EA049788B1 (ru) Композиции кольцевой рнк и способы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260213